(19) World Intellectual Property Organization International Bureau

(43) International Publication Date 16 June 2005 (16.06.2005)

(10) International Publication Number

- (51) International Patent Classification: C12Q 1/68 (2006.01)
- (21) International Application Number:

PCT/US2004/040289

(22) International Filing Date:

1 December 2004 (01.12.2004)

(25) Filing Language:

English

(26) Publication Language:

English

EP

EP

(30) Priority Data: 1 December 2003 (01.12.2003) 03090414.8 10 February 2004 (10.02.2004) 04090040.9

- 10 May 2004 (10.05.2004) 04090187.8 21 July 2004 (21.07.2004) 04090292.6 (71) Applicant (for all designated States except US): EPIGE-NOMICS AG [DE/US]; Kleine Praesidentenstrasse 1,
- (72) Inventors; and

WO 2005/054517 A3

10178 Berlin (DE).

(75) Inventors/Applicants (for US only): DAY, Kevin, J. [US/US]; 27954 251st Avenue SE, Maple Valley, WA 98038 (US). COTTRELL, Susan [US/US]; 3509 Mer dian Avenue N, Seattle, WA 98103 (US). DISTLER, Jürgen [OEfDE]; Hewaldstr. 2, 10825 Berlin (DE). MOROTTI, Andrew [US/US]; 316 Bellevue Avenue E., #402, Seattle, WA 98102 (US). YAMAMURA, Su [KR/US]; 15349 SE 42nd Street, Bellevue, WA 98006 (US). DEKKER, Sharon [US/US]; 23306 SE 209th Place, Maple Valley, WA 98038 (US). OCAMP, Yreka [US/US]; 13520 Linden Avenue N, Apt. 425, Seattle, WA 98133 (US). DEVOS, Theo [CA/US]; 1208 NE 100th Street, Seattle, WA 98125 (US).

(74) Agents: DAVISON, Barry, L. et al; 2600 Century Square, 1501 Fourth Avenue, Seattle, Wa 98101-1688 (US).

WO 2005/054517 A3


- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FT, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 16 February 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS





(57) Abstract: The following application provides methods and nucleic acids for the detection of and/or differentiation between prostate cell proliferative disorders. This is achieved by the analysis of the expression status of a panel of genes, or subsets thereof.

,	INTERNATIONAL SEARCH REP	PCT/US2004/040289			
A. CLASSIFI	CATION OF SUBJECT MATTER C12Q1/68				
According to	International Patent Classification (IPC) or to both national classification	on and IPC			
	cumentation searched (classification system followed by classification $C12Q$	symbols)			
Documentati	ion searched other than minimum documentation to the extent that su	ch documents are inc	duded in the fields searched		
	ata base consulted during the international search (name of data base cernal , WPI Data, PAJ, BIOSIS, EMBASI				
C. DOCUME	NTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the rele	vant passages	Relevant to claim No		
X	WO 02/103042 A (EPIGENOMICS AG) 27 December 2002 (2002-12-27) sequences 9, 26		1-32		
X	WO 02/103041 A (EPIGENOMICS AG; D JUERGEN; MODEL, FABIAN; ADORJAN, 27 December 2002 (2002-12-27) sequences 17, 51	1-32			
X	WO 02/18632 A (EPIGENOMICS AG; OL ALEXANDER; PIEPENBROCK, CHRISTIAN KURT;) 7 March 2002 (2002-03-07) sequences 29229, 29230, 29231	38-47			
X	WO 02/00926 A (EPIGENOMICS AG; OL ALEXANDER; PIEPENBROCK, CHRISTIAN KURT) 3 January 2002 (2002-01-03) sequences SEQ ID NO 111, 177, 258	; BERLIN,	38-47		
[V] 5	ther documents are listed in the continuation of box C	χ Patent famil	y members are listed in annex		
° Special c 'A" docum consi "E" earlier filing "L" docum which citatic 'O" docum other	ent defining the general state of the art which is not didered to be of particular relevance of document but published on or after the international date date the international date of scied to establish the publication date of another on or other special reason (as specified) the nent referring to an oral disclosure, use, exhibition or means the published prior to the international filing date but	"T" later document por pnoxty date cited to underst invention "X1 document of par cannot be consinvolve an invel "Y" document of par cannot be cons document is coments, such coin the art	published after the international filing date and not in conflict with the application but and the principle or theory underlying the dicular relevance, the claimed invention idered novel or cannot be considered to notive step when the document is taken alone ticular relevance, the claimed invention idered to involve an inventive step when the imbined with one or more other such document invention is the principle of the same patent family		
	than the priority date claimed a actual completion of the international search		of the international search report		
j	3 August 2005	2 0. 12. 2005			
Name and	mailing address of the ISA European Patent Office P B 5818 Patentlaan 2 NL - 2280 HV RIJswyk Tel (+31-70) 340-2040, Tx 31 651 epo nl. Fax (+31-70) 340-3016	Authorized officer Guarinos Vi nal s, E			

		PCT/US2004/040289			
C(Co πtIπu	atio π) DOCUMENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No			
x	wo 01/76451 A (EPIGENOMICS AG; OLEK, ALEXANDER; PIEPENBROCK, CHRISTIAN; BERLIN, KURT) 18 October 2001 (2001-10-18) sequence 27	38-47			
X	DATABASE EMBL human genomic sequence 30 April 2002 (2002-04-30) , XP002338678 Database accession no. AC063960 abstract	38-44			
x	DATABASE EMBL human EST 22 December 1999 (1999-12-22) , XP002338679 Database accessi on no. Al702131 abstract	38,42-44			
X	DATABASE EMBL human EST 24 May 2000 (2000-05-24), XP002338680 Database accession no. AW853489 abstract	38-41			
х	DATABASE EMBL human EST 1 December 2000 (2000-12-01) , XP002338681 Database accession no . BF432721 abstract	38-41			
x	DATABASE EMBL human EST 22 March 2003 (2003-03-22) , XP002338682 Database accession no. BX374481 abstract	38-41			
Α	YAMADA YASUSHI ET AL: "Aberrant methyl ati on of the vascul ar endothel i al growth factor receptor-1 gene in prostate cancer. " CANCER SCIENCE, vol. 94, no. 6, June 2003 (2003-06) , pages 536-539, XP002338911 ISSN: 1347-9032				
Α	wo 02/081749 A (UNIVERSITY OF SOUTHERN CALIFORNIA; MARKL, ISABEL; JONES, PETER, A; TOM) 17 October 2002 (2002-10-17)				
A	wo 99/55905 A (COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION; CLARK, S) 4 November 1999 (1999-11-04)				
A	wo 03/044232 A (THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE; SIDRANSKY, DAVID) 30 May 2003 (2003-05-30)				

Information on patent family members

li^Bational Application No PCT/US2004/'040289

						PC17US	2004/'040289
	tent document I in search report		Publication date		Patent family member(s)		Publication date
wo	02103042	A	27-12-2002	CA	2445731	Al	27-12-2002
				DE	10128508	Al	06-02-2003
				EP	1395686	A2	10-03-2004
				OP	2004529661	T	30-09-2004
				US	2003113750	Al	19-06-2003
wo	02103041	A	27-12-2002	DE	10128509	Al	02-01-2003
				EP	1395685	A2	10-03-2004
				us	2004219549	Al	04-11-2004
wo	0218632	A	07-03-2002	AU	1218802	A	13-03-2002
				CA	2420840	Al	27-02-2003
				EP	1423528	A2	02-06-2004
				JР	2004516821	T	10-06-2004
				MX	PA03001834	Α	01-08-2003
				US	2004234960	Al	25-11-2004
wo	0200926	A	03-01-2002	AU	7637101	A	14-01-2002
			_	ΑU	7752101	A	14-01-2002
				ΑU	7970701	Α	14-01-2002
				ΑU	8391501	Α	08-01-2002
				AU	8391601	Α	14-01-2002
				ΑU	8757501	Α	08-01-2002
				ΑU	8757601	Α	08-01-2002
				ΑŪ	8961701	Α	08-01-2002
				wo	0202806	A2	10-01-2002
				wo	0202807	A2	10-01-2002
				wo	0200927	A2	03-01-2002
				wo	0200928	A2	03-01-2002
				wo	0202808	A2	10-01-2002
				wo	0200705	A2	03-01-2002
				wo	0202809	A2	10-01-2002
				EP	1294947		26-03-2003
				EP	1297182 1294948		02-04-2003 26-03-2003
				EP EP	1294948		26-03-2003
				EP	1356099		29-10-2003
				EP	1294951	A2 A2	26-03-2003
				EP	1355932		29-10-2003
				EP	1297185	A2	02-04-2003
				ĴΡ	2004501666	T	22-01-2004
				US	2004023230	Al	05-02-2004
				US	2003143606	Al	31-07-2003
				US	2004115630	Al	17-06-2004
wo	0176451	A	18-10-2001	AU	5478801	A	23-10-2001
				ΑU	5479401	Α	23-10-2001
				AU	7566301	Α	23-10-2001
				AU	7633001	Α	23-10-2001
				ΑU	7633101	Α	23-10-2001
				ΑU	7748701	Α	23-10-2001
				AU	7842001	Α	07-11-2001
				ΑU	8960001	Α	11-12-2001
				wo	0177375		18-10-2001
				wo	0177164		18-10-2001
				wo	0177376		18-10-2001
				wo	0177377		18-10-2001
				wo	0181622	A2	01-11-2001

information on patent family members

li ational Application No PCT/US2004/040289

Patent document cited in search report		Publication date	Patent family member(s)		Publication date	
wo 0176451	A		wo	0192565	A2	06-12-2001
			wo	0177378	A2	18-10-2001
			EP	1268857	A2	02-01-2003
			EP	1272670	A2	08-01-2003
			EP	1278893	A2	29-01-2003
			EP	1274865	A2	15-01-2003
			EP	1274866	A2	15-01-2003
			EP	1360319	A2	12-11-2003
			EP	1370685	A2	17-12-2003
			EP	1268861	A2	02-01-2003
			JP	2004508807	T	25-03-2004
			JP	2003534780	T	25-11-2003
			JP	2003531589	T	28-10-2003
			US	2003082609	Al	01-05-2003
			US		Al	28-08-2003
			US	2003148326	Al	07-08-2003
			US	2004067491	Al	08-04-2004
			US		Al	07-08-2003
			US	2004076956	Al	22-04-2004
wo 02081749	Α	17-10-2002	EP	1360317		12-11-2003
			JP	2004527245	T	09-09-2004
wo 9955905	A	04-11-1999	CA	2326494	Al	04-11-1999
			EP	1071815	Al	31-01-2001
			JР	3522690	B2	26-04-2004
			JP	2002512810	T	08-05-2002
			NZ	507987		27-02-2004
			ZA	200006803	Α	10-05-2001
wo 03044232	A	30-05-2003	AU	2002352745	Al	10-06-2003
			CA	2467455		30-05-2003
			EP	1456413	Al	15-09-2004
			JР	2005509445	T	14-04-2005

rter πational application No PCT/US2004/040289

Box 11 Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons.
L. [Zj Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely See FURTHER INFORMATION sheet PCT/1SA/210
2. Claims Nos because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out specifically
3. I Claims Nos because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6 4(a).
Box iii Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions In this international application, as follows.
see additional sheet
I I As all required additional search fees were timely paid by the applicant, this International Search Report covers all Holl Searchable daims.
2] I As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee
3 I I As only some of the required additional search fees were timely paid by the applicant, this International Search Report First Brownferms Burlty Bufferful Report Report Phasing
4 Lχj, No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims, it is covered by claims Nos: 2 (completely), 1,4, 5-47 (partial ly)
Remark on Protest I The additional search fees were accompanied by the applicant's protest No protest accompanied the payment of additional search fees

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.I

Although claims 5, 14, 33 (that explicitely comprise the step of obtaining from a subject a biological sample) and claim 47 (as far as an "in vivo" method is concerned) are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Invention 1: claim 2 completely and claims 1, 4, 5-47 partially

A method for the detection of and/or differentiation between prostate cell proliferative disorders in a subject comprising contacting genomic DNA isolated from a biological sample obtained from the subject, with at least one reagent, or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within one or a combination of target nucleic acids, each of said target nucleic acids comprising essentially of all or part of the sequence of the gene or the genomic sequence SEQ ID NO: 1023, a method for detecting and/or distinguishing between or among prostate cell proliferative disorders in a subject wherein the target sequence comprises, or hybridizes under stringent conditions to at least 16 contiguous nucleotides of a sequence taken from the group consisting of SEQ ID NO: 1023, a method for detecting and/or distinguishing between or among prostate cell proliferative disorders in a subject wherein distinguishing between methylated and non methylated CpG dinucleotide sequences within the target sequence (s) comprises methylation state- dependent conversion or non-conversion of at least one CpG dinucleotide sequence to the corresponding converted or non-converted dinucleotide sequence within a sequence selected from the group consisting of SEQ ID NO: 1041 and 1042, a method for detecting and/or distinguishing between or among prostate cell proliferative disorders in a subject comprising, in each case a contiguous sequence at least 9 nucleotides in length that is complementary to or hybridizes under moderately stringent or stringent conditions to a sequence selected from the group consisting of SEQ ID NO: 1041 and 1042, a treated nucleic acid derived from SEQ ID NO:1023, a nucleic acid comprising at least 16 contiguous nucleotides of a treated genomic DNA sequence selected from the group consisting of SEQ ID NOs: 1041, 1042, 1065 and 1066, an oligomer comprising a sequence of at least 9 contiguous nucleotides that is complementary to or hybridizes under moderately stringent or stringent conditions to a treated genomic DNA sequence selected from the group consisting of SEQ ID NO: 1023, a kit comprising bisulfite reagent and an oligomer comprising a sequence of at least 9 contiguous nucleotides that is complementary to or hybridizes under moderately stringent or stringent conditions to a treated genomic DNA sequence selected from the group consisting of SEQ ID NO:1041, 1042, 1065 and 1066.

Inventions 2-17: claims 1, 3-47 partially

FURTHER INFORMATION CONTINUED FROM POT/ISA/ 210

Inventions 2-17: the same as Invention 1 but relating to SEQ ID N0:57 (GSTP1), SEQ ID N0:20 (PROSTAGLANDIN E2 RECEPTOR), SEQ ID N0:36 (HISTONE H4), SEQ ID N0:1171 (RASSFLA), SEQ ID N0:51 (PR-DOMAIN ZINC FINGER PROTEIN 16), SEQ ID N0:31 (LIM DOMAIN KINASE 1), SEQ ID N0:24 (ORPHAN NUCLEAR RECEPTOR NR5A2), SEQ ID N0:11, SEQ ID N0:1028, SEQ ID N0:4 (LIM/HOMEOBOX PROTEIN LHX9), SEQ ID N0:1116, SEQ ID N0:1025, SEQ ID N0:1020, SEQ ID N0:18 (LYSOSOMAL-ASSOCIATED MULTITRANSMEMBRANE PROTEIN), SEQ ID N0:1019 and SEQ ID N0:1027 and their respective related sequences as disclosed in Table 26, pages 140-142 of the description.

Invention 18: claims 38-47 partially

A treated nucleic acid derived from SEQ ID NO: 1, a nucleic acid comprising at least 16 contiguous nucleotides of a treated genomic DNA sequence selected from the group consisting of SEQ ID NOS: 60, 61, 178 and 179, an oligomer comprising a sequence of at least 9 contiguous nucleotides that is complementary to or hybridizes under moderately stringent or stringent conditions to a treated genomic DNA sequence of SEQ ID NO: 1, a kit comprising at least one nucleic acid molecule or peptide nucleic acid molecule comprising a contiguous sequence of at least 9 nucleotides that is complementary to or hybridizes under moderately stringent or stringent conditions to a sequence selected from the group consisting of SEQ ID NOS: 60, 61, 178 and 179, their use for the detection of and/or differentiation between or among prostate cell proliferative disorders.

Inventions 19-73: claims 38-47 partially

Inventions 19-73: the same as Invention 18 but relating to SEQ ID NOs:2, 3, 5-10, 12-17, 19, 21-23, 25-30, 32-35, 37-50, 52-56, 58-1018, 1021, 1022, 1024, 1026 and their respective related sequences as disclosed in Table 26, pages 140-142 of the description.